Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
boston top stories
7
×
deals
7
×
life sciences
national blog main
san francisco blog main
7
×
national top stories
san francisco top stories
boston
clinical trials
startups
eli lilly
genentech
hepatitis b
investing
ipo
new york blog main
new york top stories
roche
san francisco
third rock ventures
vc
warp drive bio
abbvie
acetylon pharmaceuticals
alexion pharmaceuticals
allergan
alnylam pharmaceutials
alnylam pharmaceuticals
alzheimer's disease
ambys medicines
amgen
arrowhead pharmaceuticals
avapritinib
azacitidine
beijing
beta-thalassemia
blueprint medicines
boehringer ingelheim
What
medicines
7
×
biotech
drug
new
research
alliance
cancer
deal
pact
startup
abandoning
abbvie
adds
ago
aiming
aims
ambys
approach
approval
areas
baggage
based
big
biosciences
bio’s
blueprint
brii
called
candidate
companies
control
currently
cuts
deadly
debuted
debuts
despite
developing
development
dicerna
Language
unset
Current search:
deals
×
medicines
×
" san francisco blog main "
×
biotech
×
" boston top stories "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?